BENDHEIM JACK 4
4 · PHIBRO ANIMAL HEALTH CORP · Filed May 7, 2026
Research Summary
AI-generated summary of this filing
Phibro (PAHC) 10% Owner/Director Jack Bendheim Sells Shares
What Happened
- Jack Bendheim, a 10% owner and director of Phibro Animal Health Corp (PAHC), reported multiple open‑market sales (all "S" = sale) totaling 18,608 shares for approximately $1,016,228. The trades occurred May 5–7, 2026 at reported weighted average prices of $55.73, $56.37, $57.18, $58.13, $47.59, $48.31 and $49.19 per share across the individual lots. These were disposals (sales), which are typically routine liquidity events rather than affirmative bullish signals.
Key Details
- Dates and reported lots (shares @ weighted avg. price):
- 2026-05-05: 6,264 @ $55.73 and 776 @ $56.37 (combined 7,040 shares, ~$392,810)
- 2026-05-06: 5,634 @ $57.18 and 1,406 @ $58.13 (combined 7,040 shares, ~$403,850)
- 2026-05-07: 1,350 @ $47.59, 1,149 @ $48.31, 2,029 @ $49.19 (combined 4,528 shares, ~$219,568)
- Total sold: 18,608 shares for about $1.02M. Price ranges across the multiple executions are disclosed in footnotes (roughly $47.00–$58.31 depending on lot).
- Holdings after the transactions: not specified in the provided excerpt. The filing notes some securities are directly held by Jack Bendheim and some held by BFI Co., LLC (see footnotes).
- Notable footnotes: sales were effected pursuant to a Rule 10b5‑1 trading plan adopted by BFI Co., LLC on Dec 11, 2025 (F1). The filing also clarifies that certain securities are directly held by BFI (F3) while others are directly held by Jack Bendheim (F10); Bendheim exercises voting/dispositive power over BFI but disclaims beneficial ownership except to the extent of his pecuniary interest. Weighted‑average price ranges and multiple execution details are provided in footnotes F2–F9.
- Timeliness: Report filed 2026‑05‑07 covering trades on May 5–7, 2026; this filing appears timely under Form 4 reporting rules.
Context
- These were open‑market sales under a pre‑set 10b5‑1 plan, a common mechanism insiders use to sell shares on a scheduled basis. As a 10% owner and director, Bendheim’s trades include securities held by an affiliated entity (BFI) — such filings can reflect institutional or pre‑planned liquidity rather than a personal, discretionary market view.
Insider Transaction Report
Form 4
BENDHEIM JACK
DirectorPresident and CEO10% Owner
Transactions
- Sale
Class A Common Stock
[F1][F2][F3]2026-05-05$55.73/sh−6,264$349,071→ 68,496 total(indirect: See) - Sale
Class A Common Stock
[F1][F4][F3]2026-05-05$56.37/sh−776$43,739→ 67,720 total(indirect: See) - Sale
Class A Common Stock
[F1][F5][F3]2026-05-06$57.18/sh−5,634$322,125→ 62,086 total(indirect: See) - Sale
Class A Common Stock
[F1][F6][F3]2026-05-06$58.13/sh−1,406$81,725→ 60,680 total(indirect: See) - Sale
Class A Common Stock
[F1][F7][F3]2026-05-07$47.59/sh−1,350$64,248→ 59,330 total(indirect: See) - Sale
Class A Common Stock
[F1][F8][F3]2026-05-07$48.31/sh−1,149$55,505→ 58,181 total(indirect: See) - Sale
Class A Common Stock
[F1][F9][F3]2026-05-07$49.19/sh−2,029$99,815→ 56,152 total(indirect: See)
Holdings
- 16,840
Class A Common Stock
[F10]
Footnotes (10)
- [F1]The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.
- [F10]The reported securities are directly held by Jack Bendheim.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.225 to $56.21. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 4 through 9.
- [F3]The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
- [F4]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.235 to $56.51.
- [F5]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.825 to $57.72.
- [F6]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.965 to $58.31.
- [F7]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.00 to $47.995.
- [F8]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.00 to $48.835.
- [F9]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.00 to $49.50.